1
|
Blanchot N, Béhar G, Chapuis JC, Chappuis C, Chardavoine S, Charrier JF, Coïc H, Damiens-Dupont C, Duthu J, Garcia P, Goossens JP, Granet F, Grosset-Grange C, Guerin P, Hebrard B, Hilsz L, Lamaignere L, Lacombe T, Lavastre E, Longhi T, Luce J, Macias F, Mangeant M, Mazataud E, Minou B, Morgaint T, Noailles S, Neauport J, Patelli P, Perrot-Minnot E, Present C, Remy B, Rouyer C, Santacreu N, Sozet M, Valla D, Laniesse F. 1.15 PW-850 J compressed beam demonstration using the PETAL facility. Opt Express 2017; 25:16957-16970. [PMID: 28789195 DOI: 10.1364/oe.25.016957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 05/11/2017] [Indexed: 06/07/2023]
Abstract
The Petawatt Aquitaine Laser (PETAL) facility was designed and constructed by the French Commissariat à l'énergie atomique et aux énergies alternatives (CEA) as an additional PW beamline to the Laser MegaJoule (LMJ) facility. PETAL energy is limited to 1 kJ at the beginning due to the damage threshold of the final optics. In this paper, we present the commissioning of the PW PETAL beamline. The first kJ shots in the amplifier section with a large spectrum front end, the alignment of the synthetic aperture compression stage and the initial demonstration of the 1.15 PW @ 850 J operations in the compression stage are detailed. Issues encountered relating to damage to optics are also addressed.
Collapse
|
2
|
Pettit GR, Moser BR, Boyd MR, Schmidt JM, Pettit RK, Chapuis JC. Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs. Anticancer Drug Des 2001; 16:185-93. [PMID: 12049477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The original synthesis of combretastatin A-2 (1a) was modified to provide an efficient scale-up procedure for obtaining this antineoplastic stilbene. Subsequent conversion to a useful prodrug was accomplished by phosphorylation employing in situ formation of dibenzylchlorophosphite followed by cleavage of the benzyl ester protective groups with bromotrimethylsilane to afford the phosphoric acid intermediate 11. The latter was immediately treated with sodium methoxide to complete a practical route to the disodium phosphate prodrug (2a). The phosphoric acid precursor (11) of phosphate 2a was employed in a parallel series of reactions to produce a selection of metal and ammonium cation prodrug candidates. Each of the phosphate salts (2a-q) was evaluated with respect to relative solubility behavior, cancer cell growth inhibition and antimicrobial activity.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe 85287-2404, USA
| | | | | | | | | | | |
Collapse
|
3
|
Pettit GR, Toki BE, Herald DL, Boyd MR, Hamel E, Pettit RK, Chapuis JC. Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4. J Med Chem 1999; 42:1459-65. [PMID: 10212132 DOI: 10.1021/jm9807149] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The South African willow tree Combretum caffrum has yielded a number of potent cancer cell growth inhibitors. The present SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focused mainly on the olefinic bridge to determine the effects on cancer cell growth and, potentially, to better define the combretastatin A-4 binding site on tubulin. The geometric trans-isomer 3a of combretastatin A-4 was converted to the (1S,2S)- and (1R,2R)-vicinal diols 4c and 4d, respectively, under Sharpless' asymmetric dihydroxylation conditions. Cancer cell line testing showed the (1S, 2S)-diol 4c to be more potent than its enantiomer 4d. Diol 4c weakly inhibited tubulin polymerization (IC50 = 22 microM, versus 1.2 microM for combretastatin A-4), while 4d was inactive (IC50 > 40 microM). Esterification of either stereoisomer at the diol and/or phenolic positions resulted in elimination of inhibitory activity.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute and Department of Chemistry, Arizona State University, P.O. Box 872404, Tempe, Arizona 85287-2404, USA
| | | | | | | | | | | | | |
Collapse
|
4
|
Pettit GR, Rhodes MR, Herald DL, Chaplin DJ, Stratford MR, Hamel E, Pettit RK, Chapuis JC, Oliva D. Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des 1998; 13:981-93. [PMID: 10335271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
The (E)-stilbene isomer (2a) of the (Z)-combretastatin A-4 prodrug (1b) was efficiently prepared from (E)-combretastatin A-4 by a reaction sequence employing phosphorylation (dibenzyl chlorophosphite), cleavage (trimethyliodosilane) of the benzyl ester and reaction of the resulting phosphoric acid with sodium methoxide. The sodium phosphate product (2c) was also found to be an important side-product, presumably from iodine-catalyzed isomerization, when the analogous synthetic route was used to obtain the combretastatin A-4 prodrug (1b). The phosphoric acid precursor of prodrug 1b derived from (Z)-combretastatin A-4 (1a) was converted into a series of metal cation and ammonium cation salts to evaluate effects on human cancer cell growth, antimicrobial activities and solubility behavior.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute, Arizona State University, Tempe 85287-2494, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Pettit GR, Tan R, Melody N, Cichacz ZA, Herald DL, Hoard MS, Pettit RK, Chapuis JC. Antineoplastic agents. 397: Isolation and structure of sesterstatins 4 and 5 from Hyrtios erecta (the Republic of Maldives). Bioorg Med Chem Lett 1998; 8:2093-8. [PMID: 9873492 DOI: 10.1016/s0960-894x(98)00373-4] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The wide ranging marine sponge Hyrtios erecta is the source of the spongistatins, a new class of macrocyclic lactone antineoplastic agents. Continuation of a detailed investigation of cancer cell growth inhibitory (P388 lymphocytic leukemia) fractions (trace) from H. erecta has revealed the presence (10(-5) to 10(-7)% yield) of cytotoxic pentacyclic sesterterpenes. Employing P388 leukemia and human tumor cell line-guided bioassay techniques, two new moderate inhibitors of cancer cells were isolated and named sesterstatins 4 (1a, P388 ED50 4.9 micrograms/mL) and 5 (1b, DU-145 prostate GI50 1.9 micrograms/mL). Similar to other sesterterpenes, sesterstatin 5 inhibited growth of a Gram-positive bacterium. High field (500 MHz) 2-D NMR techniques were primarily employed for initial structural assignments, and structural assignments were confirmed by X-ray crystal structure determination of sesterstatin 4 (1a) and 5 (1b).
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute, Arizona State University, Tempe 85287-2404, USA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, Pettit RK, Hogan F, Bai R, Chapuis JC, McAllister SC, Schmidt JM. Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des 1998; 13:243-77. [PMID: 9627667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The remarkable anticancer drug dolastatin 10 (1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials. Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide.
Collapse
Affiliation(s)
- G R Pettit
- Department of Chemistry, Arizona State University, Tempe, AZ 85287-2404, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Smith AB, Lin Q, Pettit GR, Chapuis JC, Schmidt JM. Synthesis and in vitro cancer cell growth inhibitory activity of monocyclic model compounds containing spongistatin triene side-chains. Bioorg Med Chem Lett 1998; 8:567-8. [PMID: 9871561 DOI: 10.1016/s0960-894x(98)00050-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Two monosaccharides embodying triene side-chains of the spongistatins display significant in vitro activity against human cancer cell lines.
Collapse
Affiliation(s)
- A B Smith
- Department of Chemistry, University of Pennsylvania, Philadelphia 19104, USA
| | | | | | | | | |
Collapse
|
8
|
Pettit GR, McNulty J, Herald DL, Doubek DL, Chapuis JC, Schmidt JM, Tackett LP, Boyd MR. Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian ocean sponge Phakellia mauritiana. J Nat Prod 1997; 60:180-183. [PMID: 9051914 DOI: 10.1021/np9606106] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Bioassay-guided isolation procedures using human tumor cell lines led to isolation of dibromophakellstatin (4) from the Republic of Seychelles sponge Phakellia mauritiana. The isolation, X-ray crystal structure elucidation, absolute stereochemistry, and antineoplastic activity have been summarized. P. mauritiana was also found to contain dibromophakellin (1), debromohymenialosine (2), thymidine, deoxyuridine, and thymine.
Collapse
Affiliation(s)
- G R Pettit
- Department of Chemistry, Arizona State University, Tempe 85287-2404, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Pettit GR, Hoard MS, Doubek DL, Schmidt JM, Pettit RK, Tackett LP, Chapuis JC. Antineoplastic agents 338. The cancer cell growth inhibitory. Constituents of Terminalia arjuna (Combretaceae). J Ethnopharmacol 1996; 53:57-63. [PMID: 8844460 DOI: 10.1016/s0378-8741(96)01421-3] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
By means of bioassay-guided separation methods, the cancer cell growth inhibitory constituents residing in the bark, stem and leaves of the Mauritius medicinal plant Terminalia arjuna (Combretaceae) were examined. The cancer cell line active components were found to be gallic acid, ethyl gallate, and the flavone luteolin. Only gallic acid was previously known to occur in this plant. Luteolin has a well established record of inhibiting various cancer cell lines and may account for most of the rationale underlying the use of T. arjuna in traditional cancer treatments. Luteolin was also found to exhibit specific activity against the pathogenic bacterium Neisseria gonorrhoeae.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute, Arizona State University, Tempe 85287-1604, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Pettit GR, Gao F, Blumberg PM, Herald CL, Coll JC, Kamano Y, Lewin NE, Schmidt JM, Chapuis JC. Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. J Nat Prod 1996; 59:286-289. [PMID: 8882431 DOI: 10.1021/np960100b] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Separation of two trace cancer cell growth inhibitory (P388 leukemia) fractions from about 1000 kg of wet Gulf of Mexico Bugula neritina (Bryozoa) has led to the isolation of bryostatins 16-18 (2-4). A combination of HRFABMS and high-field (400 MHz) 1H- and 13C-NMR spectral analyses were employed to assign the structures. The three new 20-desoxybryostatins 16 (2), 17 (3), and 18 (4) showed significant growth inhibitory activity (P388 ED50, 2, 9.3 x 10(-3) micrograms/mL, 3, 1.9 x 10(-2) micrograms/mL, and 4, 3.3 x 10(-3) micrograms/mL) against murine P388 lymphocytic leukemia.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute, Arizona State University, Tempe 85287-1604, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Durkin KP, Boyd MR, Bai R, Hamel E, Schmidt JM, Chapuis JC. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 1995; 10:529-44. [PMID: 7495477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
New structural modifications of the marine shell-less mollusk peptide constituent dolastatin 10 (1) have been synthesized, and evaluated against a variety of cancer cell lines and for their ability to inhibit tubulin polymerization. A number of useful structure-activity relationships were uncovered. The most important observation was that the dolaphenine unit of dolastatin 10 could be satisfactorily replaced with a phenethylamine. Peptide 11C, designated auristatin PE, was found to exhibit inhibition of cancer cell growth and tubulin assembly comparable to that of dolastatin 10.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute, Arizona State University, Tempe 85287-16-4, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Pettit GR, Gao F, Cerny RL, Doubek DL, Tackett LP, Schmidt JM, Chapuis JC. Antineoplastic agents. 278. Isolation and structure of axinastatins 2 and 3 from a western Caroline Island marine sponge. J Med Chem 1994; 37:1165-8. [PMID: 8164258 DOI: 10.1021/jm00034a014] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The Republic of Palau marine sponge Axinella sp. was found to be an exceptionally productive source of cell growth inhibitory substances. The strongly antineoplastic polyether macrocyclic lactones halichondrin B (1) and homohalichondrin B (2) were isolated in 1.2 x 10(-6)% and 5.4 x 10(-7)% yields, respectively. In addition to axinastatin 1 (3), two new and cytostatic (GI50 values of 0.35 to 0.0072 microgram/mL against six human cancer cell lines) cycloheptapeptides designated axinastatins 2 (4) and 3 (5) were discovered in 1.4 x 10(-6)% and 1.25 x 10(-6)% yields. Structures were elucidated by high-resolution FABMS and tandem MS/MS techniques augmented by high-field (400 and 500 MHz) 2D-NMR spectral analyses. The absolute configurations were established by a combination of hydrolysis, derivatization, and chiral gas chromatographic methods.
Collapse
Affiliation(s)
- G R Pettit
- Cancer Research Institute, Arizona State University, Tempe 85287-1604
| | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
The effects of etoposide (VP-16) and teniposide (VM-26) have been evaluated in human epidermoid carcinoma cells (A431, ME180 and HEp3) grown as exponential and plateau phase cultures. A significant increase in resistance to both these chemotherapeutic agents was observed in unfed plateau compared with exponential phase cells. The large differences in cell killing could not be explained by cell cycle specific toxicities resulting from variations in the cell cycle distributions. Rather the differences in the treatment efficacies probably reflect the 5- to 15-fold increase in the proportion of quiescent cells measured in the plateau phase cultures. These findings suggest that non-proliferating cells in tumors may be preferentially spared in treatments utilizing VP-16 and VM-26.
Collapse
Affiliation(s)
- J C Chapuis
- Tumor Biology Division, University of Rochester Cancer Center, NY 14642
| | | | | |
Collapse
|
14
|
Abstract
The effect of etoposide (VP-16) on a human epidermoid carcinoma cell line (HEp3) has been evaluated under different growth conditions. A significant increase in resistance to this agent from exponential to unfed plateau cells has been observed. Variations in the cell cycle distribution appear not to be sufficient to explain the difference in cell killing. Rather, our studies suggest the presence of an important proportion of quiescent (Q) cells in the plateau phase cultures which may determine the treatment outcome.
Collapse
Affiliation(s)
- J C Chapuis
- Experimental Therapeutics Division, University of Rochester Cancer Center, NY 14642
| | | | | |
Collapse
|
15
|
Decosterd LA, Stoeckli-Evans H, Chapuis JC, Msonthi JD, Hostettmann K. Isolation of New Cytotoxic Constituents from Hypericum revolution and Hypericum calycinum by Liquid-Liquid Chromatography. Planta Med 1988; 54:560. [PMID: 17265342 DOI: 10.1055/s-2006-962555] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Affiliation(s)
- L A Decosterd
- Institut de Pharmacognosie et Phytochimie, Ecole de Pharmacie, Université de Lausanne, 2, rue Vuillermet, CH-1005 Lausanne, Switzerland
| | | | | | | | | |
Collapse
|
16
|
Chapuis JC, Marston A, Sordat B, Hostettmann K. Investigation of Medicinal Plants for their Antiproliferative Activities Against a Human Tumour Cell Line. Planta Med 1986:553. [PMID: 17345520 DOI: 10.1055/s-2007-969365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Affiliation(s)
- J C Chapuis
- Institut de Pharmacognosie et Phytochimie, Ecole de Pharmacie, Université de Lausanne, Switzerland
| | | | | | | |
Collapse
|
17
|
Appeau A, Garcin JN, Chapuis JC. [Clinical trial of a new slow-acting antitussive preparation in a sanatorium environment]. Clinique (Paris) 1965; 60:578-580. [PMID: 5849175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|